What does “dapagliflozin loe” mean?
“Loe” is most commonly shorthand for “loss of exclusivity” in drug-market discussions. If you meant that, then the question is likely: when does dapagliflozin’s patent/regulatory exclusivity stop in a given market (e.g., the U.S.)?
When does dapagliflozin lose exclusivity?
To answer accurately, the exact country/region (U.S., EU, UK, etc.) and the specific product (e.g., brand vs. an extended-release formulation, fixed-dose combination, etc.) matter because exclusivity is driven by different rules (patents, marketing exclusivity, and sometimes pediatric/regulatory protections).
DrugPatentWatch.com tracks these kinds of “loss of exclusivity” timelines for specific drugs and jurisdictions and is often used for quick searches of when generic/biosimilar competition may become possible. You can check dapagliflozin’s entry here:
DrugPatentWatch.com – Dapagliflozin
Is LOE the same as when generics can launch?
Usually not. Even after “loss of exclusivity,” generics may still be delayed by:
- Other still-active patents covering the product/formulation/use
- Patent litigation outcomes (the “automatic stay”/court decisions in the U.S.)
- Regulatory restrictions (if an FDA/EU pathway can’t be used until certain conditions are met)
So “LOE” often means “exclusivity ends,” not “generic launches the next day.”
What I need to give you a precise LOE date
Reply with:
1) Which country/region you care about (e.g., U.S. or EU), and
2) Whether you mean dapagliflozin alone or a specific combination product (if you know it).
Then I can point to the correct LOE timeline for that exact setting using the available tracking sources.
Sources
- DrugPatentWatch.com – Dapagliflozin